K
Katherine Tarlock
Researcher at Fred Hutchinson Cancer Research Center
Publications - 49
Citations - 738
Katherine Tarlock is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 11, co-authored 36 publications receiving 456 citations. Previous affiliations of Katherine Tarlock include University of Washington & Seattle Children's.
Papers
More filters
Journal ArticleDOI
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.
Rebecca Gardner,Francesco Ceppi,Julie Rivers,Colleen Annesley,Corinne Summers,Agne Taraseviciute,Juliane Gust,Juliane Gust,Kasey J. Leger,Katherine Tarlock,Todd M. Cooper,Olivia Finney,Hannah Brakke,Daniel H. Li,Julie R. Park,Michael C. Jensen +15 more
TL;DR: The contention that early intervention with the use of tocilizumab and/or corticosteroids in subjects with early signs of CRS is without negative impact on anti-tumor potency of CD19CAR T cells is supported.
Journal ArticleDOI
Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia
Katherine Tarlock,Bill H. Chang,Todd M. Cooper,Thomas G. Gross,Sumit Gupta,Steven Neudorf,Kathleen Adlard,Phoenix A. Ho,Phoenix A. Ho,Suzanne M. McGoldrick,Tanya C. Watt,Tina Templeman,India Sisler,Amy Garee,Blythe Thomson,Ann E. Woolfrey,Ann E. Woolfrey,Elihu H. Estey,Soheil Meshinchi,Soheil Meshinchi,Jessica A. Pollard +20 more
TL;DR: FLT3/ITD is associated with poor outcomes in adult and pediatric acute myeloid leukemia (AML) and allogeneic hematopoietic stem cell transplantation can improve cure rates, however relapse is still common.
Journal ArticleDOI
Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity Management
Rebecca Gardner,Rebecca Gardner,Kasey J. Leger,Colleen Annesley,Corinne Summers,Corinne Summers,Corinne Summers,Julie Rivers,Juliane Gust,Katherine Tarlock,Todd M. Cooper,Navin R. Pinto,Olivia Finney,Hannah Smithers,Assaf P. Oron,Daniel Li,Julie R. Park,Julie R. Park,Michael C. Jensen,Michael C. Jensen +19 more
TL;DR: Early intervention with immunomodulation appears to decrease the rates of sCRS while preserving the high rates of MRD-negative CR.
Journal ArticleDOI
Pediatric Acute Myeloid Leukemia: Biology and Therapeutic Implications of Genomic Variants
TL;DR: Next-generation sequencing technologies are providing novel insights into the biology of AML and have the ability to identify potential targets for therapeutic intervention.
Journal ArticleDOI
Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group
Katherine Tarlock,Todd A. Alonzo,Robert B. Gerbing,Susana C. Raimondi,Betsy A. Hirsch,Lillian Sung,Jessica A. Pollard,Richard Aplenc,Michael R. Loken,Alan S. Gamis,Soheil Meshinchi +10 more
TL;DR: CD33 targeting with HCT consolidation may be an important therapeutic strategy in high-risk FLT3/ITD AML and its efficacy and associated toxicity warrant further investigation.